Hyperfunction of pituitary gland, other and/or unspecified

E4_HYPERPITNAS

hyperpituitarism: Disease of the glandular, anterior portion of the pituitary (pituitary gland, anterior) resulting in hypersecretion of adenohypophyseal hormones such as growth hormone; prolactin; thyrotropin; luteinizing hormone; follicle stimulating hormone ; and adrenocorticotropic hormone. Hyperpituitarism usually is caused by a functional adenoma.

Suggest a new description

Endpoint definition

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 E22.9
  • Hospital discharge: ICD-9 2531X
  • Hospital discharge: ICD-8 25301
  • Cause of death: ICD-10 E22.9
  • Cause of death: ICD-9 2531X
  • Cause of death: ICD-8 25301

2 out of 7 registries used, show all original rules.

58

4. Check minimum number of events

None

58

5. Include endpoints

None

58

6. Filter based on genotype QC (FinnGen only)

58

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
E22
Name in latin
Hyperfunctio hypophysis non specificata

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 363 231 131
Only index persons 324 212 112
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.00
Median age at first event (years)
Whole population 46.68 44.04 51.12
Only index persons 45.20 41.70 51.83

-FinnGen-

Key figures

All Female Male
Number of individuals 58 37 21
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 49.23 44.67 57.26

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
58
Matched controls
580
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E22.9
ICD-10 Finland
Hyperfunction of pituitary gland, unspecified
+∞
69.4
52
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
29.8
26
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
23.5
21
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
19.9
18
*
H02AB09
ATC
hydrocortisone; systemic
99.2
19.1
20
*
N04BC06
ATC
cabergoline; oral
197.8
15.2
15
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
14.1
13
*
G02CB01
ATC
bromocriptine; systemic
43.1
13.4
16
5
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
13.0
12
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
13.0
12
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
118.6
9.7
10
*
H03AA01
ATC
levothyroxine sodium; systemic
5.5
9.5
29
89
2530A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Acromegaly and gigantism[ACROMEGALIA]
+∞
8.5
8
*
H01CB02
ATC
octreotide; parenteral
+∞
7.4
7
*
G02CB03
ATC
cabergoline; oral
+∞
7.4
7
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
7.4
7
*
UJF32
NOMESCO Finland
Coloscopy
4.2
6.8
28
105
25301
ICD-8 Finland
Diseases of pituitary gland, Gigantismus hypophysarius et hyperpituitarismus alius
+∞
6.4
6
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
11.0
6.1
11
12

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
6
0
+∞
6.35
2.0
0.0
189.67
—
mu/l
—
6
0
6
0
+∞
6.35
2.2
0.0
—
—
—
0
0
6
0
+∞
6.35
2.0
0.0
79.83
—
%
—
6
0
11
28
4.60
3.51
5.2
2.0
12.21
15.22
nmol/l
0.51
11
28
50
375
3.41
3.17
8.1
3.8
15.47
14.78
pmol/l
0.87
50
340
26
138
2.60
3.07
3.9
4.2
0.00
0.00
estimate
—
8
44
39
256
2.60
2.90
3.8
3.6
0.00
0.00
estimate
—
8
44
11
35
3.63
2.83
2.3
3.3
—
—
—
0
0
38
253
2.46
2.65
3.9
3.7
0.00
0.00
estimate
—
9
51
11
38
3.33
2.59
1.5
1.2
—
—
—
0
0
26
148
2.37
2.56
7.4
3.5
7.39
7.40
ph
—
6
20
11
43
2.92
2.23
14.4
4.0
0.60
0.73
%
—
5
15
7
19
4.04
2.23
3.9
5.1
—
—
—
0
0
37
257
2.21
2.16
5.2
4.7
0.00
0.00
estimate
—
8
47
6
17
3.81
1.89
1.0
1.6
—
264.03
—
0
7
22
133
2.05
1.76
3.5
2.3
337.14
9426.37
umol/l
1.06
22
111
19
112
2.04
1.61
5.2
4.1
—
—
—
0
0
6
21
3.06
1.55
1.5
1.2
—
—
—
0
0
9
42
2.35
1.41
6.3
3.7
—
—
—
0
0
6
23
2.79
1.40
4.5
2.8
0.88
1.19
%
—
6
23
6
23
2.79
1.40
4.5
2.8
0.65
0.70
%
—
6
23
8
34
2.56
1.35
13.4
7.9
—
—
—
0
0
20
129
1.84
1.28
7.0
7.4
—
—
—
0
0
8
37
2.34
1.27
6.4
3.6
1.09
2.54
mmol/l
—
8
28
21
143
1.73
1.11
2.7
3.2
—
—
—
0
0
7
33
2.27
1.10
5.6
3.2
1.23
1.21
mmol/l
—
7
28
27
198
1.68
1.09
1.9
2.0
—
—
—
0
0
19
127
1.74
1.06
3.8
4.0
—
—
—
0
0
14
87
1.80
0.99
1.4
1.7
436.57
537.94
pmol/l
0.72
14
79
6
27
2.36
0.96
4.5
3.2
118.50
125.48
g/l
—
6
27
6
27
2.36
0.96
11.7
10.1
85.82
93.47
%
—
6
27
21
148
1.66
0.96
3.6
2.9
—
—
—
0
0
20
140
1.65
0.94
4.5
2.0
—
—
—
0
0
10
58
1.88
0.86
2.2
1.6
—
—
—
0
0
6
32
1.97
0.84
2.3
1.3
—
—
—
0
0
10
59
1.84
0.82
2.9
2.9
2.04
1.58
%
—
10
53
20
145
1.58
0.80
3.2
2.0
162.15
147.14
u/l
0.09
20
139
9
53
1.82
0.80
2.1
1.6
—
—
—
0
0
17
119
1.61
0.78
5.3
3.7
—
—
—
0
0
7
38
1.96
0.77
6.9
3.5
—
—
—
0
0
5
25
2.09
0.74
2.0
2.2
—
—
—
0
0
9
58
1.65
0.74
10.0
7.2
105.33
104.05
mmol/l
—
9
58
21
157
1.53
0.73
5.6
3.1
2.32
2.35
mmol/l
0.44
21
139
13
88
1.62
0.68
1.5
1.5
1316.54
1342.00
nmol/l
0.03
13
72
7
44
1.67
0.68
1.9
1.6
—
—
—
0
0
24
188
1.47
0.66
1.5
1.8
78.76
94.59
pmol/l
1.28
14
94
5
29
1.79
0.65
1.2
1.8
—
—
—
0
0
10
64
1.68
0.63
1.3
1.2
—
—
—
0
0
18
134
1.50
0.63
3.6
2.5
—
—
—
0
0
12
81
1.61
0.63
2.4
1.8
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
19
0.00
0.61
0.0
2.8
—
—
—
0
0
15
108
1.52
0.61
2.8
2.3
7.70
5.11
e6/l
0.33
15
94
39
340
1.45
0.59
5.4
4.0
—
—
—
0
0
6
37
1.69
0.57
2.0
3.8
—
—
—
0
0
27
222
1.40
0.56
15.8
6.4
—
—
—
0
0
6
40
1.56
0.53
11.0
2.6
—
—
—
0
0
27
225
1.37
0.51
20.1
11.4
1.18
1.28
inr
—
9
64
13
95
1.47
0.49
3.9
2.6
512.23
569.70
mosm/kgh2o
0.63
13
77
7
50
1.45
0.47
9.0
2.7
67.83
67.31
g/l
—
7
44
8
56
1.50
0.45
2.4
1.5
—
—
—
0
0
12
89
1.44
0.42
3.1
3.1
2.41
2.45
mmol/l
0.44
12
81
0
15
0.00
0.42
0.0
1.3
—
9.16
—
0
5
21
173
1.34
0.41
3.0
2.4
—
—
—
0
0
5
36
1.42
0.39
1.6
1.7
—
—
—
0
0
9
70
1.34
0.39
3.0
1.4
—
—
—
0
0
53
504
1.60
0.39
27.5
14.2
3.95
3.97
mmol/l
0.23
53
490
53
501
1.67
0.38
27.4
14.3
140.00
139.74
mmol/l
0.40
53
487
7
51
1.42
0.33
1.1
1.3
—
—
—
0
0
50
515
0.79
0.28
20.9
11.7
—
—
—
0
0
51
490
1.34
0.24
22.6
13.5
26.12
22.95
mg/l
0.24
43
379
26
233
1.21
0.23
12.2
5.3
58.23
56.97
%
0.24
26
220
16
137
1.23
0.22
1.6
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
7
60
1.19
0.18
1.4
1.8
116.86
69.42
ug/g
—
7
50
7
60
1.19
0.18
1.0
1.3
—
—
—
0
0
31
287
1.17
0.18
7.1
4.0
7.06
6.50
mmol/l
0.45
31
273
25
228
1.17
0.17
16.2
5.5
2.12
2.52
%
0.68
25
213
25
230
1.15
0.15
16.5
5.8
7.57
8.42
%
0.91
25
217
11
94
1.21
0.14
1.3
1.3
1.08
13.44
u/ml
—
6
35
16
144
1.15
0.12
4.9
4.8
2.72
2.03
ug/l
0.54
16
127
39
373
1.14
0.12
5.4
4.5
18.82
11.50
mm/h
0.92
39
343
44
425
1.15
0.10
25.3
15.8
14.38
14.82
%
0.30
44
419
12
107
1.15
0.09
1.5
1.2
0.43
0.75
u/ml
—
6
27
53
520
1.22
0.09
28.1
15.1
82.51
75.35
umol/l
1.39
53
520
7
64
1.11
0.08
1.9
1.7
31.43
23.64
%
—
7
56
25
236
1.10
0.08
16.3
5.5
29.57
27.98
%
0.29
25
222
7
67
1.05
0.08
1.3
1.5
—
498.67
—
0
15
35
340
1.07
0.04
4.4
3.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
14.08
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
78
0.88
-0.00
1.4
1.6
16.40
15.12
umol/l
—
7
71
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
71
0.98
-0.00
1.6
1.6
2.18
2.39
g/l
—
7
64
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.3
—
16.00
—
0
9
0
5
0.00
-0.00
0.0
1.4
—
1.63
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
90.54
—
0
5

Mortality – FinRegistry

Association

Association between endpoint E4_HYPERPITNAS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_HYPERPITNAS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

Index endpoint: E4_HYPERPITNAS – Hyperfunction of pituitary gland, other and/or unspecified

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data